KLRC1 and neoplasm: Our study showed that NK cells expressing immune checkpoints (including NKG2A and KIRs that typically inhibit NK cell function upon HLA-I recognition) are enriched in tumor tissues from CRC patients regardless of the tumor stage and MSI/MSS status.